Qi et al. “AT9283, a novel aurora kinase inhibitor suppresses tumor growth in aggressive B-cell lymphomas.” International Journal of Cancer 2011. DOI: 10.1002/ijc.26324.

/in ,

Qi et al. “AT9283, a novel aurora kinase inhibitor suppresses tumor growth in aggressive B-cell lymphomas.” International Journal of Cancer 2011. DOI: 10.1002/ijc.26324.

Santo et al. “Antimyeloma Activity of a Multitargeted Kinase Inhibitor, AT9283, via Potent Aurora Kinase and STAT3 Inhibition Either Alone or in Combination with Lenalidomide.” Clinical Cancer Research 17, no. 10 2011: 3259–71. DOI: 10.1158/1078-0432.CCR-10-3012.

/in ,

Santo et al. “Antimyeloma Activity of a Multitargeted Kinase Inhibitor, AT9283, via Potent Aurora Kinase and STAT3 Inhibition Either Alone or in Combination with Lenalidomide.” Clinical Cancer Research 17, no. 10 2011: 3259–71. DOI: 10.1158/1078-0432.CCR-10-3012.

Squires et al. “Potent, selective inhibitors of Fibroblast Growth Factor Receptor define Fibroblast Growth Factor dependence in pre-clinical cancer models.” Molecular Cancer Therapeutics 10, no. 22 2011: 1542-1552. DOI: 10.1158/1535-7163.MCT-11-0426.

/in ,

Squires et al. “Potent, selective inhibitors of Fibroblast Growth Factor Receptor define Fibroblast Growth Factor dependence in pre-clinical cancer models.” Molecular Cancer Therapeutics 10, no. 22 2011: 1542-1552. DOI: 10.1158/1535-7163.MCT-11-0426.

Verdonk et al. “Docking performance of fragments and drug-like compounds.” Journal of Medicinal Chemistry 54, no. 15 2011: 5422–5431. DOI: 10.1021/jm200558u.

/in ,

Verdonk et al. “Docking performance of fragments and drug-like compounds.” Journal of Medicinal Chemistry 54, no. 15 2011: 5422–5431. DOI: 10.1021/jm200558u.

Williams, Glyn. “The pyramid approach to fragment-based biophysical screening.” In Label-Free Technologies for Drug Discovery, edited by Matthew Cooper and Lorenz M. Mayr, 241-253. Chichester, UK: John Wiley & Sons Ltd 2011. ISBN: 978-0-470-74683-7.

/in ,

Williams, Glyn. “The pyramid approach to fragment-based biophysical screening.” In Label-Free Technologies for Drug Discovery, edited by Matthew Cooper and Lorenz M. Mayr, 241-253. Chichester, UK: John Wiley & Sons Ltd 2011. ISBN: 978-0-470-74683-7.

Yap et al. “Preclinical Pharmacology, Antitumor Activity, and Development of Pharmacodynamic Markers for the Novel, Potent AKT Inhibitor CCT128930.” Molecular Cancer Therapeutics 10, no. 2 2011: 360-71. DOI: 10.1158/1535-7163.MCT-10-0760.

/in ,

Yap et al. “Preclinical Pharmacology, Antitumor Activity, and Development of Pharmacodynamic Markers for the Novel, Potent AKT Inhibitor CCT128930.” Molecular Cancer Therapeutics 10, no. 2 2011: 360-71. DOI: 10.1158/1535-7163.MCT-10-0760.

Cho et al. “4-(Pyrazol-4-yl)-pyrimidines as Selective Inhibitors of Cyclin-Dependent Kinase 4/6.” Journal of Medicinal Chemistry 53, no. 22 2010: 7938–7957. DOI: 10.1021/jm100571n.

/in ,

Cho et al. “4-(Pyrazol-4-yl)-pyrimidines as Selective Inhibitors of Cyclin-Dependent Kinase 4/6.” Journal of Medicinal Chemistry 53, no. 22 2010: 7938–7957. DOI: 10.1021/jm100571n.

Christopher W. Murray and Tom L. Blundell. “Structural Biology in Fragment-Based Drug Design.” Current Opinion in Structural Biology 20, no. 4 2010: 497-507. DOI: 10.1016/j.sbi.2010.04.003.

/in ,

Christopher W. Murray and Tom L. Blundell. “Structural Biology in Fragment-Based Drug Design.” Current Opinion in Structural Biology 20, no. 4 2010: 497-507. DOI: 10.1016/j.sbi.2010.04.003.

Dawson M. A. et al. “AT9283, a potent inhibitor of the Aurora kinases and Jak2, has therapeutic potential in myeloproliferative disorders.” British Journal of Haematology 150, no. 1 2010: 46-57. DOI: 10.1111/j.1365-2141.2010.08175.x.

/in ,

Dawson M. A. et al. “AT9283, a potent inhibitor of the Aurora kinases and Jak2, has therapeutic potential in myeloproliferative disorders.” British Journal of Haematology 150, no. 1 2010: 46-57. DOI: 10.1111/j.1365-2141.2010.08175.x.

McHardy et al. “Discovery of 4-Amino-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamides As Selective, Orally Active Inhibitors of Protein Kinase B (Akt).” Journal of Medicinal Chemistry 53, no. 5 2010: 2239–2249. DOI: 10.1021/jm901788j.

/in ,

McHardy et al. “Discovery of 4-Amino-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamides As Selective, Orally Active Inhibitors of Protein Kinase B (Akt).” Journal of Medicinal Chemistry 53, no. 5 2010: 2239–2249. DOI: 10.1021/jm901788j.